Skip to main content
Erschienen in: Cardiovascular Drugs and Therapy 3/2016

22.02.2016 | ORIGINAL ARTICLE

Burden of Coronary Heart Disease Rehospitalizations Following Acute Myocardial Infarction in Older Adults

verfasst von: Emily B. Levitan, Paul Muntner, Ligong Chen, Luqin Deng, Meredith L. Kilgore, David Becker, Stephen P. Glasser, Monika M. Safford, George Howard, Ryan Kilpatrick, Robert S. Rosenson

Erschienen in: Cardiovascular Drugs and Therapy | Ausgabe 3/2016

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Studies of prognosis following acute myocardial infarction (AMI) conventionally examine the first recurrent coronary heart disease (CHD) event which may not adequately characterize the full burden of CHD hospitalizations. We therefore examined the cumulative number of CHD rehospitalizations following AMI among older adults in the United States.

Methods

We conducted a retrospective cohort study of 78,085 Medicare beneficiaries aged ≥66 years without recent CHD history who were hospitalized for AMI in 2000–2010. Counts of CHD rehospitalizations over a maximum of 10 years of follow-up were calculated. Characteristics were assessed through claims and enrollment information and associations with CHD rehospitalizations were evaluated using Poisson models.

Results

Over 25 % of beneficiaries were aged ≥85 years, 55 % were women, and 89 % were white. Comorbidities were common, including diabetes (22.9 %), hypertension (46.7 %), heart failure (10.3 %), and chronic obstructive pulmonary disease (19.2 %). Following AMI, 16,078 beneficiaries (20.6 %) were hospitalized for CHD a total of 23,132 times. Among those who experienced at least one CHD rehospitalization, 35.9 % had ≥2 CHD rehospitalizations (n = 5773, 7.4 % of all beneficiaries with AMI) in the ensuing decade. Associations of demographics, comorbidities, and index hospitalization characteristics with rates of first and total CHD rehospitalizations were largely similar. Age ≥85 years versus 66–69 years was more strongly associated with first (rate ratio [RR] 1.43) than total (RR 1.35) CHD rehospitalization (p < 0.05), as was male versus female sex (RR 1.13 and 1.07).

Conclusions

Emphasizing the first recurrent CHD rehospitalization underestimates the burden of disease experienced among older adults with AMI.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
2.
Zurück zum Zitat Nissen SE. Cardiovascular outcomes in randomized trials: should time to first event for “hard” end points remain the standard approach? J Am Coll Cardiol. 2009;54(25):2363–5.CrossRefPubMed Nissen SE. Cardiovascular outcomes in randomized trials: should time to first event for “hard” end points remain the standard approach? J Am Coll Cardiol. 2009;54(25):2363–5.CrossRefPubMed
3.
Zurück zum Zitat Smith SC, Benjamin EJ, Bonow RO, Braun LT, Creager MA, Franklin BA, et al. AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 Update: a guideline from the American Heart Association and American College of Cardiology Foundation. Circulation. 2011;124(22):2458–73.CrossRefPubMed Smith SC, Benjamin EJ, Bonow RO, Braun LT, Creager MA, Franklin BA, et al. AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 Update: a guideline from the American Heart Association and American College of Cardiology Foundation. Circulation. 2011;124(22):2458–73.CrossRefPubMed
4.
Zurück zum Zitat Stone NJ, Robinson J, Lichtenstein AH, Merz CNB, Blum CB, Eckel RH et al. 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2013. Stone NJ, Robinson J, Lichtenstein AH, Merz CNB, Blum CB, Eckel RH et al. 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2013.
5.
Zurück zum Zitat Eckel RH, Jakicic JM, Ard JD, de Jesus JM, Houston Miller N, Hubbard VS, et al. 2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(25 suppl 2):S76–99.CrossRefPubMed Eckel RH, Jakicic JM, Ard JD, de Jesus JM, Houston Miller N, Hubbard VS, et al. 2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(25 suppl 2):S76–99.CrossRefPubMed
6.
Zurück zum Zitat Eagle KA, Lim MJ, Dabbous OH, Pieper KS, Goldberg RJ, Van de Werf F, et al. A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month postdischarge death in an international registry. JAMA. 2004;291(22):2727–33.CrossRefPubMed Eagle KA, Lim MJ, Dabbous OH, Pieper KS, Goldberg RJ, Van de Werf F, et al. A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month postdischarge death in an international registry. JAMA. 2004;291(22):2727–33.CrossRefPubMed
7.
Zurück zum Zitat Anavekar NS, McMurray JJ, Velazquez EJ, Solomon SD, Kober L, Rouleau JL, et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med. 2004;351(13):1285–95.CrossRefPubMed Anavekar NS, McMurray JJ, Velazquez EJ, Solomon SD, Kober L, Rouleau JL, et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med. 2004;351(13):1285–95.CrossRefPubMed
8.
Zurück zum Zitat Murphy SA, Cannon CP, Wiviott SD, McCabe CH, Braunwald E. Reduction in recurrent cardiovascular events with intensive lipid-lowering statin therapy compared with moderate lipid-lowering statin therapy after acute coronary syndromes from the PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) trial. J Am Coll Cardiol. 2009;54(25):2358–62.CrossRefPubMed Murphy SA, Cannon CP, Wiviott SD, McCabe CH, Braunwald E. Reduction in recurrent cardiovascular events with intensive lipid-lowering statin therapy compared with moderate lipid-lowering statin therapy after acute coronary syndromes from the PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) trial. J Am Coll Cardiol. 2009;54(25):2358–62.CrossRefPubMed
9.
Zurück zum Zitat Tikkanen MJ, Szarek M, Fayyad R, Holme I, Cater NB, Faergeman O, et al. Total cardiovascular disease burden: comparing intensive with moderate statin therapy insights from the IDEAL (Incremental Decrease in End Points Through Aggressive Lipid Lowering) trial. J Am Coll Cardiol. 2009;54(25):2353–7.CrossRefPubMed Tikkanen MJ, Szarek M, Fayyad R, Holme I, Cater NB, Faergeman O, et al. Total cardiovascular disease burden: comparing intensive with moderate statin therapy insights from the IDEAL (Incremental Decrease in End Points Through Aggressive Lipid Lowering) trial. J Am Coll Cardiol. 2009;54(25):2353–7.CrossRefPubMed
10.
Zurück zum Zitat Kent ST, Safford MM, Zhao H, Levitan EB, Curtis JR, Kilpatrick RD, et al. Optimal use of available claims to identify a medicare population free of coronary heart disease. Am J Epidemiol. 2015;182(9):808–19.CrossRefPubMed Kent ST, Safford MM, Zhao H, Levitan EB, Curtis JR, Kilpatrick RD, et al. Optimal use of available claims to identify a medicare population free of coronary heart disease. Am J Epidemiol. 2015;182(9):808–19.CrossRefPubMed
11.
Zurück zum Zitat Kiyota Y, Schneeweiss S, Glynn RJ, Cannuscio CC, Avorn J, Solomon DH. Accuracy of medicare claims-based diagnosis of acute myocardial infarction: estimating positive predictive value on the basis of review of hospital records. Am Heart J. 2004;148(1):99–104.CrossRefPubMed Kiyota Y, Schneeweiss S, Glynn RJ, Cannuscio CC, Avorn J, Solomon DH. Accuracy of medicare claims-based diagnosis of acute myocardial infarction: estimating positive predictive value on the basis of review of hospital records. Am Heart J. 2004;148(1):99–104.CrossRefPubMed
12.
Zurück zum Zitat Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med. 1999;18(6):695–706.CrossRefPubMed Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med. 1999;18(6):695–706.CrossRefPubMed
13.
Zurück zum Zitat Davison AC, Hinkley DV. Bootstrap methods and their application. New York: Cambridge University Press; 1997.CrossRef Davison AC, Hinkley DV. Bootstrap methods and their application. New York: Cambridge University Press; 1997.CrossRef
14.
Zurück zum Zitat Prentice RL, Williams BJ, Peterson AV. On the regression analysis of multivariate failure time data. Biometrika. 1981;68(2):373–9.CrossRef Prentice RL, Williams BJ, Peterson AV. On the regression analysis of multivariate failure time data. Biometrika. 1981;68(2):373–9.CrossRef
15.
Zurück zum Zitat Box-Steffensmeier JM, De Boef S. Repeated events survival models: the conditional frailty model. Stat Med. 2006;25(20):3518–33.CrossRefPubMed Box-Steffensmeier JM, De Boef S. Repeated events survival models: the conditional frailty model. Stat Med. 2006;25(20):3518–33.CrossRefPubMed
16.
Zurück zum Zitat Rogers JK, Pocock SJ, McMurray JJ, Granger CB, Michelson EL, Ostergren J, et al. Analysing recurrent hospitalizations in heart failure: a review of statistical methodology, with application to CHARM-Preserved. Eur J Heart Fail. 2014;16(1):33–40.CrossRefPubMed Rogers JK, Pocock SJ, McMurray JJ, Granger CB, Michelson EL, Ostergren J, et al. Analysing recurrent hospitalizations in heart failure: a review of statistical methodology, with application to CHARM-Preserved. Eur J Heart Fail. 2014;16(1):33–40.CrossRefPubMed
17.
Zurück zum Zitat Borer JS, Bohm M, Ford I, Komajda M, Tavazzi L, Sendon JL, et al. Effect of ivabradine on recurrent hospitalization for worsening heart failure in patients with chronic systolic heart failure: the SHIFT Study. Eur Heart J. 2012;33(22):2813–20.CrossRefPubMedPubMedCentral Borer JS, Bohm M, Ford I, Komajda M, Tavazzi L, Sendon JL, et al. Effect of ivabradine on recurrent hospitalization for worsening heart failure in patients with chronic systolic heart failure: the SHIFT Study. Eur Heart J. 2012;33(22):2813–20.CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Anderson JL, Heidenreich PA, Barnett PG, Creager MA, Fonarow GC, Gibbons RJ, et al. ACC/AHA statement on cost/value methodology in clinical practice guidelines and performance measures: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures and Task Force on Practice Guidelines. Circulation. 2014;129(22):2329–45.CrossRefPubMed Anderson JL, Heidenreich PA, Barnett PG, Creager MA, Fonarow GC, Gibbons RJ, et al. ACC/AHA statement on cost/value methodology in clinical practice guidelines and performance measures: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures and Task Force on Practice Guidelines. Circulation. 2014;129(22):2329–45.CrossRefPubMed
19.
Zurück zum Zitat Weintraub WS, Cohen DJ. The limits of cost-effectiveness analysis. Circ: Cardiovasc Qual Outcomes. 2009;2(1):55–8. Weintraub WS, Cohen DJ. The limits of cost-effectiveness analysis. Circ: Cardiovasc Qual Outcomes. 2009;2(1):55–8.
Metadaten
Titel
Burden of Coronary Heart Disease Rehospitalizations Following Acute Myocardial Infarction in Older Adults
verfasst von
Emily B. Levitan
Paul Muntner
Ligong Chen
Luqin Deng
Meredith L. Kilgore
David Becker
Stephen P. Glasser
Monika M. Safford
George Howard
Ryan Kilpatrick
Robert S. Rosenson
Publikationsdatum
22.02.2016
Verlag
Springer US
Erschienen in
Cardiovascular Drugs and Therapy / Ausgabe 3/2016
Print ISSN: 0920-3206
Elektronische ISSN: 1573-7241
DOI
https://doi.org/10.1007/s10557-016-6653-6

Weitere Artikel der Ausgabe 3/2016

Cardiovascular Drugs and Therapy 3/2016 Zur Ausgabe

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.